Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of about $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

 

Loading ....

Comments

Leave a Reply

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.